Nigel J. Bundred, Ian D. Campbell, Neville Davidson, Richard H. DeBoer, Holger Eidtmann, Alain Monnier, Patrick Neven, Gunter von Minckwitz, Joel C. Miller, Nora L. Schenk and Robert E. Coleman Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole Cancer 112
Version of Record online: 18 JAN 2008 | DOI: 10.1002/cncr.23259
Aromatase inhibitors may be associated with bone loss and higher incidence of fracture; this 5-year study was designed to evaluate the effectiveness of immediate versus delayed bone protection therapy with zoledronic acid. After 1 year, results from the ZO-FAST trial indicated that immediate 4 mg zoledronic acid therapy administered on a 6-month schedule prevented bone loss in postmenopausal women who were receiving adjuvant letrozole for early stage breast cancer.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field